Skip to Content

Research

PALLAS

Research

Research

Clinicaltrial.gov identifier:
NCT02513394
Status:
Recruiting
Scenario:
Adjuvant
Tumour subtype:
HR+
Phase:
Phase III
Drug/Intervention:
Palbociclib

Phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2-negative early breast cancer

A randomized phase III trial of Palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Collaborators

Breast International Group
Austrian Breast and Colorectal Cancer Group
NSABP Foundation Inc
PrECOG, LLC.
Pfizer

Principal investigators

Erica L. Mayer, MD, MPH

Susan F Smith Center for Women’s Cancers, Dana-Farber Cancer Institute

Angela DeMichele MD MSCE

Abramson Cancer Center, University of Pennsylvania

Michael Gnant MD

Austrian Breast & Colorectal Cancer Study Group Universidad Médica de Viena

X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.